Recent developments of HSP90 inhibitors: an updated patent review (2020-present).

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL Expert Opinion on Therapeutic Patents Pub Date : 2024-01-01 Epub Date: 2024-03-08 DOI:10.1080/13543776.2024.2327295

Jianfeng Liu, Huangliang Shu, Qinxin Xia, Qidong You, Lei Wang

{"title":"Recent developments of HSP90 inhibitors: an updated patent review (2020-present).","authors":"Jianfeng Liu, Huangliang Shu, Qinxin Xia, Qidong You, Lei Wang","doi":"10.1080/13543776.2024.2327295","DOIUrl":null,"url":null,"abstract":"Introduction: The 90-kDa heat shock protein (HSP90) functions as a molecular chaperone, it assumes a significant role in diseases such as cancer, inflammation, neurodegeneration, and infection. Therefore, the research and development of HSP90 inhibitors have garnered considerable attention.Areas covered: The primary references source for this review is patents obtained from SciFinder, encompassing patents on HSP90 inhibitors from the period of 2020 to 2023.This review includes a thorough analysis of their structural attributes, pharmacological properties, and potential clinical utilities.Expert opinion: In the past few years, HSP90 inhibitors targeting ATP binding pocket are still predominate and one of them has been launched, besides, novel drug design strategies like C-terminal targeting, isoform selective inhibiting and bifunctional molecules are booming, aiming to improve the efficacy and safety. With expanded drug types and applications, HSP90 inhibitors may gradually becoming a sagacious option for treating various diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2024.2327295","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The 90-kDa heat shock protein (HSP90) functions as a molecular chaperone, it assumes a significant role in diseases such as cancer, inflammation, neurodegeneration, and infection. Therefore, the research and development of HSP90 inhibitors have garnered considerable attention.

Areas covered: The primary references source for this review is patents obtained from SciFinder, encompassing patents on HSP90 inhibitors from the period of 2020 to 2023.This review includes a thorough analysis of their structural attributes, pharmacological properties, and potential clinical utilities.

Expert opinion: In the past few years, HSP90 inhibitors targeting ATP binding pocket are still predominate and one of them has been launched, besides, novel drug design strategies like C-terminal targeting, isoform selective inhibiting and bifunctional molecules are booming, aiming to improve the efficacy and safety. With expanded drug types and applications, HSP90 inhibitors may gradually becoming a sagacious option for treating various diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HSP90 抑制剂的最新进展：最新专利回顾（2020 年至今）。

引言90-kDa热休克蛋白（HSP90）作为一种分子伴侣，在癌症、炎症、神经变性和感染等疾病中发挥着重要作用。因此，HSP90 抑制剂的研究和开发受到了广泛关注：本综述的主要参考资料来源是从 Scifinder 获得的专利，涵盖 2020 年至 2023 年期间有关 HSP90 抑制剂的专利。本综述包括对其结构属性、药理特性和潜在临床用途的全面分析：过去几年中，以ATP结合口袋为靶点的HSP90抑制剂仍占主导地位，其中一种已经上市，此外，C端靶向、同种异构体选择性抑制和双功能分子等新型药物设计策略也在蓬勃发展，旨在提高疗效和安全性。随着药物种类和应用领域的扩大，HSP90 抑制剂可能逐渐成为治疗各种疾病的明智选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.